Michael Gladstone

Michael Gladstone is the founder of Q32 Bio Operations, Inc. Mr. Gladstone is currently Director at Kailera Therapeutics, Inc. since 2024.
Mr. Gladstone is Director at DOT Therapeutics-2, Inc. Mr. Gladstone is Independent Director at Third Harmonic Bio, Inc. since 2019.
Mr. Gladstone is Non-Executive Director & Board Member at Versanis Bio, Inc. Mr. Gladstone is Director at Diagonal Therapeutics, Inc. Mr. Gladstone is Director at Aiolos Bio, Inc. Mr. Gladstone is Partner at Atlas Venture Advisors, Inc. since 2020.
Mr. Gladstone is Principal at Padlock Therapeutics, Inc. Mr. Gladstone is Partner at Atlas Venture Life Science Advisors LLC since 2020.
Mr. Gladstone is Board Member at Pheon Therapeutics Ltd. since 2022.
Formerly, Mr. Gladstone was Independent Director at Day.
One Biopharmaceuticals, Inc. Mr. Gladstone was Operations Director at Spero Therapeutics, Inc. Mr. Gladstone was Director-Business Operations at Surface Oncology, Inc. Mr. Gladstone was Director at Replimune Group, Inc. Mr. Gladstone was Director at AVROBIO, Inc. Mr. Gladstone was Director at IFM Therapeutics LLC.
Mr. Gladstone was Director at Delinia, Inc. Mr. Gladstone was Director at Indalo Therapeutics, Inc. Mr. Gladstone was Director at Akero Therapeutics, Inc. Mr. Gladstone was Director at Xilio Therapeutics LLC.
Mr. Gladstone was Senior Associate Consultant at The Lek.
Mr. Gladstone was Principal at Beth Israel Deaconess Medical Center, Inc. Mr. Gladstone completed undergraduate education at Harvard College in 2009.